SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study

A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kyriakos, Georgios, Quiles-Sanchez, Lourdes V., Garmpi, Anna, Farmaki, Paraskevi, Kyre, Konstantina, Savvanis, Spyridon, Antoniou, Vasileios K., Memi, Eleni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903507/
https://www.ncbi.nlm.nih.gov/pubmed/31362691
http://dx.doi.org/10.2174/1573403X15666190730094215
_version_ 1783654752041566208
author Kyriakos, Georgios
Quiles-Sanchez, Lourdes V.
Garmpi, Anna
Farmaki, Paraskevi
Kyre, Konstantina
Savvanis, Spyridon
Antoniou, Vasileios K.
Memi, Eleni
author_facet Kyriakos, Georgios
Quiles-Sanchez, Lourdes V.
Garmpi, Anna
Farmaki, Paraskevi
Kyre, Konstantina
Savvanis, Spyridon
Antoniou, Vasileios K.
Memi, Eleni
author_sort Kyriakos, Georgios
collection PubMed
description A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied.
format Online
Article
Text
id pubmed-7903507
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Bentham Science Publishers
record_format MEDLINE/PubMed
spelling pubmed-79035072021-11-01 SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study Kyriakos, Georgios Quiles-Sanchez, Lourdes V. Garmpi, Anna Farmaki, Paraskevi Kyre, Konstantina Savvanis, Spyridon Antoniou, Vasileios K. Memi, Eleni Curr Cardiol Rev Article A new group of hypoglycemic drugs has been used to treat diabetes type 2. This group is active sodium glucose co-transporter (SGLT2) or SGLT2 inhibitors. It has been shown that besides the treatment of diabetes, this drug class is responsible for the mildness of the cardiovascular events shown in patients with diabetes type 2. However, there is an intriguing question regarding the range of SGLT2 inhibitors and if there is a difference between them or if there is a class effect among their results. EMPA-REG OUTCOME trial and the CVD-study are used to answer this question. Additional information from the DECLARE-TIMI 58 and Dapa-HF trials is studied. Bentham Science Publishers 2020-11 2020-11 /pmc/articles/PMC7903507/ /pubmed/31362691 http://dx.doi.org/10.2174/1573403X15666190730094215 Text en © 2020 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
spellingShingle Article
Kyriakos, Georgios
Quiles-Sanchez, Lourdes V.
Garmpi, Anna
Farmaki, Paraskevi
Kyre, Konstantina
Savvanis, Spyridon
Antoniou, Vasileios K.
Memi, Eleni
SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
title SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
title_full SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
title_fullStr SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
title_full_unstemmed SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
title_short SGLT2 Inhibitors and Cardiovascular Outcomes: Do They Differ or There is a Class Effect? New Insights from the EMPA-REG OUTCOME trial and the CVD-REAL Study
title_sort sglt2 inhibitors and cardiovascular outcomes: do they differ or there is a class effect? new insights from the empa-reg outcome trial and the cvd-real study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903507/
https://www.ncbi.nlm.nih.gov/pubmed/31362691
http://dx.doi.org/10.2174/1573403X15666190730094215
work_keys_str_mv AT kyriakosgeorgios sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT quilessanchezlourdesv sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT garmpianna sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT farmakiparaskevi sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT kyrekonstantina sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT savvanisspyridon sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT antoniouvasileiosk sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy
AT memieleni sglt2inhibitorsandcardiovascularoutcomesdotheydifferorthereisaclasseffectnewinsightsfromtheemparegoutcometrialandthecvdrealstudy

Ejemplares similares